Quick Answer
ENANTA PHARMACEUTICALS INC reported Cash and Equivalents of $32.30 million for fiscal year 2025.
ENANTA PHARMACEUTICALS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $32.30M | -13.3% |
| 2024 | $37.23M | -56.4% |
| 2023 | $85.39M | +94.1% |
| 2022 | $43.99M | -23.1% |
| 2021 | $57.21M | -34.3% |
| 2020 | $87.13M | +70.1% |
| 2019 | $51.23M | -19.8% |
| 2018 | $63.90M | -2.7% |
| 2017 | $65.67M | +296.2% |
| 2016 | $16.58M | -23.7% |
| 2015 | $21.73M | -29.2% |
| 2014 | $30.70M | +246.5% |
| 2013 | $8.86M | -15.7% |
| 2012 | $10.51M | +53.7% |
| 2011 | $6.84M | +1367.2% |
| 2010 | $466.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $37.44M | -55.6% | +15.9% |
| September 30, 2025 | $32.30M | -13.3% | -27.9% |
| June 30, 2025 | $44.81M | +25.3% | -25.6% |
| March 31, 2025 | $60.21M | -5.2% | -28.6% |
| December 31, 2024 | $84.35M | +111.2% | +126.5% |
| September 30, 2024 | $37.23M | -56.4% | +4.1% |
| June 30, 2024 | $35.77M | -62.4% | -43.7% |
| March 31, 2024 | $63.54M | -13.2% | +59.1% |
- ENANTA PHARMACEUTICALS INC showed a decrease of -13.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, ENANTA PHARMACEUTICALS INC’s cash and equivalents has grown by 6830.9% (from $466.0 thousand to $32.30 million).
- The most recent figure is from ENANTA PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 19, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: